Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q2 2022 · 10-Q
Revenue$152.37M$152.37M+11.7% vs Q2 2021 Net Income$22.69M$22.69M−75.2% vs Q2 2021 EPS Diluted$0.16$0.16−74.2% vs Q2 2021 Operating Income$34,060,000−63.4% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$39,257,000+8.0% Margins · derivedOperating margin22.4%−45.8 pt vs Q2 2021
Net margin14.9%−52.1 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 9, 2022 · 40 d after period end